Diamyd Medical and Protein Sciences deepen commitment to develop new treatment for diabetes

Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) and Protein Sciences Corporation announced today that Protein Sciences has broadened its commitment to diabetes and become a strategic and significant shareholder in Diamyd Medical, its long-time partner in this domain. Protein Sciences will manufacture product for upcoming late stage clinical trials for type 1 diabetes involving Diamyd Medical’s recombinant GAD (glutamic acid decarboxylase) protein made using Protein Sciences’ proprietary Baculovirus Expression Vector System (BEVS) technology. The diabetes vaccine Diamyd® (GAD